Aiolos Bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $980M
Overview
Developing antibody therapies for asthma and other inflammatory respiratory conditions.
RespiratoryImmunology
Technology Platform
Focuses on developing monoclonal antibodies that target key cytokines, like TSLP, involved in inflammatory pathways.
Funding History
4Total raised:$980M
Series D$245M
Series C$245M
Series B$245M
Series A$245M
Opportunities
There is a large, growing patient population seeking more convenient and effective biologic treatments for moderate-to-severe asthma.
Risk Factors
Clinical trials may fail to show sufficient differentiation or superiority against established, branded competitors.
Competitive Landscape
Competes with several approved and late-stage biologics for asthma (e.g., anti-IL-4/13, anti-IL-5, anti-IgE) in a crowded market.